Patient-derived cell-based pharmacogenomic assessment to unveil underlying resistance mechanisms and novel therapeutics for advanced lung cancer

BACKGROUND: A pharmacogenomic platform using patient-derived cells (PDCs) was established to identify the underlying resistance mechanisms and tailored treatment for patients with advanced or refractory lung cancer. METHODS: Drug sensitivity screening and multi-omics datasets were acquired from lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Namhee, Hwang, Mihwa, Lee, Youngjoo, Song, Bo Ram, Kang, Eun Hye, Sim, Hanna, Ahn, Beung-Chul, Hwang, Kum Hui, Kim, Jihyun, Hong, Sehwa, Kim, Sunshin, Park, Charny, Han, Ji-Youn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885631/
https://www.ncbi.nlm.nih.gov/pubmed/36717865
http://dx.doi.org/10.1186/s13046-023-02606-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885631/
https://www.ncbi.nlm.nih.gov/pubmed/36717865
http://dx.doi.org/10.1186/s13046-023-02606-3

Ejemplares similares